Reading Time: < 1 minute

SAN JOSE, Calif.–(BUSINESS WIRE)–HighTech Business Decisions has just published its new study: “Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2019.” This 300-page report details both the prices paid by biotechnology companies and prices charged by biopharmaceutical contract manufacturing organizations for large-molecule drug substance production using either mammalian cell culture or microbial fermentation technologies by specific bioreactor sizes. In addition, this report documents prices paid and prices charged for other services offered by the contract manufacturing organizations, including cell banking, cell-line development, process development, technology transfer, and regulatory support.

William Downey, president of HighTech Business Decisions, explained, “According to the biotechnology and contract manufacturing executives, overall contract manufacturing prices have increased at an average annual rate of 5% over the past five years. However, because of productivity gains, we continue to see a downward trend on production prices when normalized on a price-per-gram basis. Most respondents expect to see higher prices in the future with general price increases across the board.”

This report provides the reader with over 200 detailed charts and tables covering industry trends, prices, and selected contract terms such as reservation and cancellation fees, price models and fee-for-service arrangements. In addition to production prices, this report also documents hourly rates by major functional areas.

About HighTech Business Decisions

HighTech Business Decisions is a market research and consulting firm specializing in biopharmaceutical contract manufacturing. The company has been producing in-depth public reports and customized market research for over twenty years. Visit us at


William Downey

HighTech Business Decisions